Potential and challenges in application of physiologically based pharmacokinetic modeling in predicting diarrheal disease impact on oral drug pharmacokinetics

被引:2
|
作者
Zhang, Cindy X. [1 ]
Arnold, Samuel L. M. [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, 1959 NE Pacific St, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
Physiologically based pharmacokinetic; Absorption; Infectious diseases; SMALL-INTESTINAL TRANSIT; INFLAMMATORY-BOWEL-DISEASE; REGULATORY DECISION-MAKING; IN-VIVO PERFORMANCE; CELIAC-DISEASE; CYCLOSPORINE-A; GASTROINTESTINAL TRANSIT; BACTERIAL OVERGROWTH; EFFLUX TRANSPORTERS; ULCERATIVE-COLITIS;
D O I
10.1124/dmd.122.000964
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Physiologically based pharmacokinetic (PBPK) modeling is a physiologically relevant approach that integrates drug-specific and system parameters to generate pharmacokinetic predictions for target populations. It has gained immense popularity for drug-drug interaction, organ impairment, and special population studies over the past 2 decades. However, an application of PBPK modeling with great potential remains rather overlookeddprediction of diarrheal disease impact on oral drug pharmacokinetics. Oral drug absorption is a complex process involving the interplay between physicochemical characteristics of the drug and physiological conditions in the gastrointestinal tract. Diarrhea, a condition common to numerous diseases impacting many worldwide, is associated with physiological changes in many processes critical to oral drug absorption. In this Minireview, we outline key processes governing oral drug absorption, provide a high-level overview of key parameters for modeling oral drug absorption in PBPK models, examine how diarrheal diseases may impact these processes based on literature findings, illustrate the clinical relevance of diarrheal disease impact on oral drug absorption, and discuss the potential and challenges of applying PBPK modeling in predicting disease impacts. Significance Statement: Pathophysiological changes resulting from diarrheal diseases can alter important factors governing oral drug absorption, contributing to suboptimal drug exposure and treatment failure. Physiologically based pharmacokinetic (PBPK) modeling is an in silico approach that has been increasingly adopted for drug-drug interaction potential, organ impairment, and special population assessment. This Minireview highlights the potential and challenges of using physiologically based pharmacokinetic modeling as a tool to improve our understanding of how diarrheal diseases impact oral drug pharmacokinetics. (c) 2024 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions
    Ono, Chiho
    Hsyu, Poe-Hirr
    Abbas, Richat
    Loi, Cho-Ming
    Yamazaki, Shinji
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (04) : 390 - 398
  • [2] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING IN PREDICTING DRUG-DRUG INTERACTIONS FOR TELMISARTAN IN HUMANS
    Kim, Jeong Ho
    Heo, Hyunjin
    Min, Jee Sun
    Kim, Doyun
    Bae, Soo Hyeon
    Bae, Soo Kyung
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S109 - S110
  • [3] Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery
    Wang, Wei
    Ouyang, Defang
    DRUG DISCOVERY TODAY, 2022, 27 (08) : 2100 - 2120
  • [4] Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery
    Shi, Jian
    Zha, Weibin
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (01) : 135 - 137
  • [5] Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery
    Jian Shi
    Weibin Zha
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 135 - 137
  • [6] PREDICTING NONLINEAR PHARMACOKINETICS OF OMEPRAZOLE ENANTIOMERS AND RACEMIC DRUG USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING AND SIMULATION
    Wu, F.
    Zhao, P.
    Lee, S. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S85 - S85
  • [7] Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans
    Min, Jee Sun
    Kim, Doyun
    Park, Jung Bae
    Heo, Hyunjin
    Bae, Soo Hyeon
    Seo, Jae Hong
    Oh, Euichaul
    Bae, Soo Kyung
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 2959 - 2972
  • [8] Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions
    Fang Wu
    Lu Gaohua
    Ping Zhao
    Masoud Jamei
    Shiew-Mei Huang
    Edward D. Bashaw
    Sue-Chih Lee
    Pharmaceutical Research, 2014, 31 : 1919 - 1929
  • [9] Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions
    Wu, Fang
    Lu Gaohua
    Zhao, Ping
    Jamei, Masoud
    Huang, Shiew-Mei
    Bashaw, Edward D.
    Lee, Sue-Chih
    PHARMACEUTICAL RESEARCH, 2014, 31 (08) : 1919 - 1929
  • [10] Physiologically based pharmacokinetic modeling of DMB in rats for predicting its pharmacokinetics in humans
    Lee, Kyeong-Ryoon
    Chae, Jung-Byung
    Yim, Chang-Soon
    Kim, Dae-Duk
    Chong, Saeho
    Shim, Chang-Koo
    Chung, Suk-Jae
    DRUG METABOLISM REVIEWS, 2011, 43 : 72 - 73